Incyte and Gene Logic Settle Patent Infringement Lawsuit PALO ALTO, Calif. & GAITHERSBURG, Md.-January 10, 2001-Incyte Genomics, Inc. (Nasdaq: INCY) and Gene Logic Inc. (Nasdaq: GLGC), announced today a litigation settlement related to patent infringement lawsuits filed by Incyte against Gene Logic in the United States District Court for the Northern District of California alleging infringement of U.S. Patent Numbers 5,716,785, 5,891,636 and 6,023,659. Under the settlement, the lawsuits will be dismissed and Gene Logic will have a non–exclusive license to practice the technology described in these patents. In accordance with the terms of the settlement agreement, specific settlement and financial terms were not disclosed. Incyte Overview Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at http://www.incyte.com. Gene Logic Overview Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and development of pharmaceutical, biotechnology, health care, and life science products through the systematic and industrialized application of genomics and bioinformatics. Gene Logic has built and is commercializing the world's most comprehensive survey of gene expression in human and animal tissues. Gene expression, which is the degree to which genes in a cell are switched on or off, or regulated, is information critical to understanding the functions of genes. Gene Logic markets two types of gene expression database products to the global pharmaceutical, biotechnology, health care and life science industries: its custom databases and related software products and the GeneExpress® Suite of databases. The GeneExpress® Suite can be used to discover and validate novel drug targets, develop and prioritize therapeutic compounds and facilitate clinical trials and patient management. Today, a number of pharmaceutical and biotechnology companies use Gene Logic's various gene expression products for drug discovery, predictive toxicology and diagnostic applications. For more information about Gene Logic, visit the company's Web site at http://www.genelogic.com or telephone toll-free on 1-800-GENELOGIC. Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. For a discussion of factors that may cause results to differ, see Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2000, and Gene Logic's Annual Report on Form 10-K for the year ended December 31, 1999 and Gene Logic's other SEC reports, including its Quarterly Reports on Form 10-Q. Incyte and Gene Logic disclaim any intent or obligation to update these forward-looking statements.